News Hub | News Direct

MGC Pharmaceuticals reveals strategic objectives for H1 2024

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd CEO and Managing Director Roby Zomer speaks to Thomas Warner from Proactive London following the completion of a share consolidation and capital raise. With these restructuring initiatives completed, Zomer shares his enthusiasm for the future of the plant-based pharmaceutical company and outlines the strategic roadmap for 2024. Zomer emphasises the importance of the recent share consolidation, which involved restructuring the company's capital and introducing new investors aligned with MGC Pharma's long-term vision as a pharmaceutical entity. The CEO highlighted that this move would facilitate the execution of the company's 2024 work plan, presented over the past six months during various roadshows. Acknowledging the impact of the restructuring on existing shareholders, Zomer expresses optimism about the real opportunity it now presents. He explained that the capital raised in the past 18 months, coupled with new long-term investors, positions MGC Pharma to build a sustainable future, providing returns to shareholders who faced dilution. Looking ahead to 2024, Zomer outlined key initiatives in the company's work plan. The focus will be on completing studies on CimetrA, a drug with potential applications, to enable submission to the FDA for an Investigational New Drug (IND) designation. Simultaneously, ongoing clinical trials will pave the way for seeking early access schemes in the United States and eventually obtaining marketing authorization globally. The second drug, CannEpil, designed for drug-resistant epilepsy, will also undergo enrolment and IND submission, with efforts split evenly between both drugs. Zomer highlights the commercial focus on CannEpil in the UK and Ireland, but says CimetrA takes precedence in terms of IND submission, with both drugs considered essential for the company's progress. As the pharmaceutical landscape evolves, Zomer anticipates increased sales of CimetrA through existing schemes, additional purchase orders, and revenue growth. By mid-2024, Zomer envisions CimetrA entering the IND process, with results from dose-finding studies and the initiation of the IND submission for CanAppeal. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 14, 2023 12:57 PM Eastern Standard Time

Video

Health History on the Menu: This Thanksgiving Pass the Pumpkin Pie--and Grandma’s Health History

YourUpdateTV

Thanksgiving is a day filled with food, football, and conversations with family. While loved ones spend time together safely this Thanksgiving, they should consider talking about family health history. Recently, Susan Manley, senior vice president of Medical Services at Myriad Genetics and Ashley Dedmon, breast cancer previvor conducted a satellite media tour to talk about the importance of initiating health conversations at your holiday gathering. A video accompanying this announcement is available at: https://youtu.be/j0VMnkq1ij4 More than half (55%) of respondents to a recent Myriad Genetics Cancer Risk survey of women said that it’s important to know their cancer risk for “peace of mind.” Yet, 20% of women say they don’t talk about health issues in their family. This has potentially life-threatening consequences. Patients with a family history of breast, ovarian, uterine, or colorectal cancer may have a higher risk for developing these cancers. Getting answers to these questions may qualify your viewers for genetic hereditary cancer testing, which can help people and their clinician determine if they are at an increased risk of developing specific types of cancer. November is Family Health History Month. Encourage your audience to talk about family health history – it may save some lives. Myriad Genetics has an easy-to-complete family health history form to help start the conversation and take notes. During the holiday season, people can bring this form along to family gatherings and complete it by asking as many blood relatives, parents and grandparents, aunts and uncles, sisters and brothers about their family history. To learn more visit: myriad.com/KNOWYOURHISTORY BIOS Susan Manley, MS, MBA Senior Vice President, Medical Services Myriad Genetics, Inc. Salt Lake City, Utah Susan received her undergraduate degree in Biological Sciences from the University of Wisconsin-Milwaukee with a certification in biotechnology, her Master’s degree in Genetic Counseling from the University of Cincinnati, and her MBA from Loyola University in Maryland. She is an American Board of Genetic Counseling certified Genetic Counselor and holds a Genetic Counselor license in the state of Utah. She has been employed at Myriad Genetics for the past 28 years in both medical support and commercialization capacities and has been involved in the development of the commercial genetic testing market from medical, ethical, clinical, counseling, sales and marketing standpoints. Currently, she oversees a large staff of licensed genetic counselors who provide professional customer support and patient education for Myriad’s hereditary cancer and prenatal products. She is published in the medical literature including JAMA, JCO and Breast Cancer Research and Treatment. This combination of clinical knowledge and commercialization experience is unique and valuable in precision medicine space. Ashley Dedmon Breast cancer has impacted Ashley Demon’s family since before she was born - three generations of women in her family have been impacted by this disease. Ashley’s great grandmother, grandmother and mother all passed away from breast cancer, Ashley’s mother at only 42, when Ashley was 21. Cancer didn't stop there: her father was diagnosed with prostate cancer. Ashley’s hereditary mutations heightened her cancer risk. After taking the MyRisk® Hereditary Cancer Test, she learned she carried the BRCA2 gene mutation, putting her at an elevated risk for breast, ovarian and other cancers. After her first daughter had successfully weaned from breastfeeding, Ashley consulted with her doctors and came to the decision to have a prophylactic mastectomy, a procedure which could significantly reduce her risk of developing breast cancer. Since then, Ashley’s been living a normal life and has since given birth to a second daughter. Ashley’s doctors continue to actively monitor her health. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 14, 2023 10:00 AM Eastern Standard Time

Video

With New Lab/Operations Hub, Cardio Diagnostics Says it’s Prepared To Meet Uptake In Demand, Announces New Partner Initiative

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Nearly 50% of Americans live with diabetes, obesity, hypertension or another major cardiovascular risk, according to the Centers for Disease Control and Prevention (CDC). For many Americans, the first sign of coronary heart disease (CHD) is a heart attack. A recent announcement by Cardio Diagnostics (NASDAQ: CDIO) details a bright future for the company’s AI-driven molecular heart disease tests, which evaluate objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease. After securing an Innovation Technology contract with Vizient, Inc. — the nation’s largest provider-driven healthcare performance improvement company — Cardio Diagnostics will have access to a potential customer base that encompasses greater than 60% of hospitals and 97% of academic medical centers in the United States. On the flip side, Vizient provider customers will have access to Cardio Diagnostics' state-of-the-art tests at negotiated pricing, thereby increasing access to the next generation of cardiovascular disease detection technology. The contract, effective Nov. 1, signifies to Vizient hospital and health system customers a shift toward unique technology that has the potential to bring improvement and cost savings to the healthcare industry. Vizient’s diverse customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers. The company represents more than $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with customer-led councils and task forces to review potentially innovative products. This new contract with Cardio Diagnostics demonstrates Vizient’s confidence in the company’s Epi+Gen CHD and PrecisionCHD tests, which utilize proprietary laboratory assays and AI-driven algorithms to analyze objective epigenetic and genetic biomarkers from a patient's blood sample. Scaling The Business Based in part on the new contract with Vizient and what it believes to be increasing interest in its epigenetic tests, Cardio Diagnostics is preparing to fulfill demand while keeping costs down through the launch of a new facility. Last month, Cardio Diagnostics announced the launch of a new integrated facility in Iowa City, Iowa, that will house a research laboratory, high-complexity Clinical Laboratory Improvement Amendments (CLIA) laboratory and fulfillment center. The new hub will work as the epicenter for distributing sample collection kits to clients and performing all laboratory research and commercial testing. With a modular setup, the high-complexity CLIA laboratory will enable Cardio Diagnostics to process up to 10,000 tests per month while reducing laboratory processing costs by up to 60%. Those fees currently account for the largest portion of the cost of goods sold. Cardio Diagnostics reports that performing kitting and fulfillment of sample collection kits internally further reduces this cost by up to 56%. By integrating operations in-house, Cardio Diagnostics expects to meaningfully improve its gross profit margin while continuing to explore opportunities to further scale capacity and drive down costs. In addition to its pioneering Epi+Gen CHD and PrecisionCHD tests, Cardio Diagnostics is expanding its diagnostic portfolio, by developing tests for stroke, diabetes and heart failure at this new facility. This horizontal integration approach broadens the company's market reach, catering to a more comprehensive range of cardiovascular diseases across the care continuum. By accelerating the development of its product portfolio, Cardio Diagnostics not only enhances its market positioning but also aligns with the trend towards comprehensive, multi-faceted diagnostic solutions in healthcare. Initial operations at this facility are expected to commence in Q4 2023, with full operations anticipated in Q1 2024. "Establishing an internal high-complexity CLIA lab will facilitate the development of a testing process that can be completed in under four hours,” said Robert Philibert, MD Ph.D., Cardio Diagnostics’ Chief Medical Officer. “This time frame fits well with our vision of our heart disease diagnostic tests being eventually offered as essentially point-of-care tests, with a same-day turnaround in almost all medical markets.” With the Vizient contract in place, demand for Cardio Diagnostics tests will soon be higher than ever before. The launch of Cardio Diagnostics’ operational hub will increase distribution and sample processing capabilities, helping the company fulfill demand while fostering continued innovation and setting new standards to improve patient outcomes globally through low-cost precision cardiovascular diagnostics. This progress will assist in furthering detection for the many individuals at risk for and impacted by cardiovascular disease. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website http://www.cardiodiagnosticsinc.com/

November 14, 2023 09:25 AM Eastern Standard Time

Precision Medicine Helps Conquer Advanced-Stage Cancer

MarketJar

As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According to Miyo Yamashita, President and CEO of The Princess Margaret Cancer Foundation, in the last five to 10 years, our understanding of cancer has surpassed what we learned in the preceding 50 years. Yamashita emphasized progress in molecular research, genomic sequencing, and personalized therapies surpassing conventional methods like surgery, radiation, and chemotherapy. For cancer survivor Jenny Young, precision medicine has been life changing. Unlike one-size-fits-all treatments, precision medicines consider genetic variabilities in individual cancer cases. At 41, she discovered a lethal tumor during a post-wedding world tour. Initially attributing symptoms to exhaustion, declining health led her to seek medical assistance. Despite a stage four cancer diagnosis, traditionally deemed terminal, recent breakthroughs in cancer care altered Young's prognosis. Treatment options extended her life beyond the initial four to six weeks projected by doctors, challenging the perception of her survival as a mere miracle. The answer was a life-saving cancer medicine called Osimertinib, marketed under the brand name Tagrisso. The medication works by attaching to a EGFR protein in cancer cells and stopping its activity, which helps prevent the cancer from growing. Young has been taking the medication for four years now and while it won't cure her, it can effectively contain the issue for the time being. Acknowledging the pervasive impact of cancer, she expressed hope in innovative treatments, citing clinical trials. Among the companies developing therapies for the expanding oncology market is Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), a Canadian biopharmaceutical company specializing in cancer vaccines and drug delivery technologies. The company collaborates with the academic laboratory of Dr. Moutih Rafei, a globally recognized expert in immuno-oncology, to advance the development of next-generation vaccines and Antibody-Drug Conjugate (ADC) products. At the heart of Defence Therapeutics ’ platform is its ACCUM® technology, which enables precision delivery of vaccine antigens to target cells, enhancing the effectiveness and strength of treatments against severe illnesses like cancer and infectious diseases. This innovative technology has demonstrated the capability to deliver treatments at a rate ten times faster than other approved solutions, marking a significant advancement in the field. Defence Therapeutics Submits IND to the FDA for Anti Cancer Drug On November 14, Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) hit a major milestone with the successful submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its injectable anticancer molecule AccuTOX ® for the treatment of solid tumors. AccuTOX®, evolving from the original Accum® molecule, combats cancer by disrupting cell processes, blocking DNA repair in cancer cells, and triggering a cell death that activates the immune system. In studies led by Dr. Moutih Rafei, AccuTOX® significantly reduced tumor growth in animals, achieving a survival rate of 70-100% in cases of lymphoma, melanoma, and breast cancer. The IND application for Defence Therapeutics ' AccuTOX® includes comprehensive data on its pharmacological effects, safety in both laboratory and animal cancer models, and details on its production for human clinical trials. This application is aimed at demonstrating to the FDA the safety of AccuTOX® for initial human administration. With FDA approval, Defence Therapeutics could begin Phase I clinical trials as early as the first or second quarter of 2024. Click here or visit their website for more information about Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF). Disclosure: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Defence Therapeutics Inc. Market Jar Media Inc. has or expects to receive from Defence Therapeutics Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) ninety six thousand five hundred US dollars for 30 days (21 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Defence Therapeutics Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Defence Therapeutics Inc.’s industry; (b) market opportunity; (c) Defence Therapeutics Inc.’s business plans and strategies; (d) services that Defence Therapeutics Inc. intends to offer; (e) Defence Therapeutics Inc.’s milestone projections and targets; (f) Defence Therapeutics Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Defence Therapeutics Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Defence Therapeutics Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Defence Therapeutics Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Defence Therapeutics Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Defence Therapeutics Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Defence Therapeutics Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Defence Therapeutics Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Defence Therapeutics Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Defence Therapeutics Inc.’s business operations (e) Defence Therapeutics Inc. may be unable to implement its growth strategy; and (f) increased competition.Except as required by law, Defence Therapeutics Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Defence Therapeutics Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Defence Therapeutics Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Defence Therapeutics Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Defence Therapeutics Inc. or such entities and are not necessarily indicative of future performance of Defence Therapeutics Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

November 14, 2023 09:00 AM Eastern Standard Time

Image

CoverSelf lands $8.2m to drive healthcare claims and payment accuracy

CoverSelf

Helping to reduce claims inaccuracies and waste, CoverSelf, a unified platform for healthcare claims and payment integrity, is today announcing a $8.2m seed round as it successfully deploys platform in the ecosystem. The funding round was led by existing investors BEENEXT and 3one4 Capital with participation from new investor Z21 ventures and healthtech leaders. The fresh capital will be used to grow operations, build generative AI capabilities, and increase headcount in sales and marketing as the business scales. The exponential growth of costs in healthcare remains a hotly debated and ever-evolving problem around the world. Over $4.1 trillion is spent on healthcare every year in the US alone, with administrative spending accounting for approximately one-quarter of the total amount. Founded in 2021 by seasoned US healthcare domain experts Rajasekhar Maddireddy and Raghavendra Pawar, CoverSelf aims to democratize the healthcare claims and payment integrity industry by creating a first-of-its-kind fully-open and transparent solution that empowers payment integrity teams in health insurance companies (payers) to transparently resolve health claims with hospitals and medical practices (providers). “The current claims integrity systems are very complex, and the deployed technologies are antiquated. Significant software innovation is needed to address the broken system that is currently creating out-of-control healthcare costs and waste. The cobbled-together software solutions result in scattered data and the inability to make real-time business decisions. Administrative complexity costs billions annually, an open and collaborative platform can significantly reduce the repetitive administrative costs.” commented Rajasekhar Maddireddy, Founder of CoverSelf. Over the last 12 months, the company has piloted the platform and successfully proved the platform’s readiness and effectiveness. This has translated to two deployments for insurers where the platform processes 25 times more claims in the same time window than was done earlier. Also, the platform has identified significant savings even after other vendors process claims. CoverSelf is in advanced discussions with 2 of the top 15 plans to collaborate. The current pipeline includes five of the top 15. “One platform, one configuration, one team – our solution offers multiple points of integration and intervention for all pre and post-pay payment integrity, effectively reducing waste. CoverSelf empowers subject matter experts (SMEs) with a modern UX/UI that's super easy to work with and aids them by eliminating technical dependencies while maximizing efficiency, and fostering rapid innovation. Speed to release has shifted from weeks to mere hours, thanks to our collaborative approach and operational efficiency,” said Raghavendra Pawar. Traditional third-party payment integrity solution vendors exploit payment inaccuracies, which negatively impacts the provider’s experience and trust in payers and ends up ballooning waste and improper payments. With CoverSelf, payor payment integrity teams can reduce healthcare costs transparently and collaboratively with providers. “Having worked with several of the largest health plans in the US, I have seen first-hand the unmet needs and improvement potential in their claims and payment integrity processes. That is why I am very excited to work with CoverSelf, which is the most innovative PI solution that I have come across. I firmly believe that not only is the next-gen, cloud-native, built-from-scratch platform that CoverSelf has created unique in its capabilities, CoverSelf’s value proposition of empowering payer internal PI teams to take back control from 3rd party vendors is also very appealing – several ex-clients who have met with CoverSelf have told me that this is the most differentiated offering that they have seen to date”, said Ashish Singh, ex-Global Healthcare Practice Leader and 30 year partner with Bain & Company. CoverSelf’s purpose-built platform utilizes multiple approaches to reduce waste while identifying new savings opportunities. The platform empowers payers to adapt to claims and payment inaccuracies by enabling them to configure their policies and logic in simple English-like language or use simple policy-specific templates, overcoming the fear of losing IP and fostering innovation and new concept releases without technical dependencies. “CoverSelf is in the process of building pathbreaking features with GenAI. We aim to change how payment integrity is approached and executed with these cutting-edge features. Our vision remains steadfast--we want to empower payer PI teams and make them first-class citizens of payment integrity rather than have third-party vendors controlling it. Currently, GenAI is in stealth mode, and we are working with the stakeholders to add an outstanding and simplified user experience. With that said, we welcome our new investors and thank our existing backers for their continued confidence!” added Rajasekhar Maddireddy, Co-founder of CoverSelf. On leading the investment, Dirk Van Quaquebeke, Managing Partner, BEENEXT commented: “According to the Centers for Medicare and Medicaid (CMS), Americans spent $4.1 trillion on healthcare in 2020, of which an estimated $1.2 trillion can be attributed to some form of waste or abuse that leads to overcharges. CoverSelf’s vision to democratize the healthcare claims and payment integrity industry with their fully open and transparent solution built with a spirit of collaboration is truly inspirational.” Meanwhile, Sonal Saldanha, VP Investments at 3One4 Capital said: “By bringing the payment integrity solution in-house, CoverSelf shifts the control of payment integrity from traditional outside vendors to payers. As payers start using CoverSelf, they will progressively need fewer external payment integrity vendors. Ultimately, CoverSelf will be the only payment integrity platform anyone will ever need." About BEENEXT BEENEXT is a Venture Capital fund managed by serial entrepreneurs that focuses on assisting founders with their operational experience, network, trust, unique perspectives, and capital. The team invests in early-stage tech start-ups that are focused on building the new digital platforms driven by the data network. BEENEXT is a platform of founders, by the founders and for the founders across the globe. Since its establishment in 2015, the team has invested in over 200 companies globally. For more information, please visit www.beenext.com About 3one4 Capital 3one4 Capital is an early-stage venture capital fund. The firm works in select market categories and in the intersection of adjacencies that are large, growing, and ready for unique products and services. The themes pursued are SaaS and Enterprise Automation, Direct-to-Consumer products and services, Digital Media, FinTech, and Deep Technology, with a focus on areas such as machine-driven actionable intelligence services for the enterprise, ambient intelligence technologies, health, edtech, logistics and distribution, and consumer products and services. Through a deep involvement strategy, the fund works with founding teams and subject-matter experts to prioritize and strategize for product-market fit, and then optimize for defensibility and growth in revenue and impact. With a focus on margins and on delivering uncompromised end-user experiences, the fund aims to reduce risk, detect new growth opportunities, and return rewarding outcomes to all the stakeholders involved Contact Details CoverSelf Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.coverself.com/

November 14, 2023 09:00 AM Eastern Standard Time

Image

Creo Medical CEO "very happy with where we are at the moment"

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after the minimally invasive electrosurgical device company announced positive news on its Speedboat UltraSlim product. The UltraSlim variant of Creo's Speedboat product has received FDA clearance in the US, and has also been granted an unexpectedly short regulatory pathway into European markets. Gulliford emphasises the significance of the technology, highlighting its unique ability to effectively use bipolar radiofrequency for cutting in surgery. The UltraSlim model, the culmination of extensive engineering efforts, represents another significant step forward for Creo Medical. With the scientific groundwork completed, Gulliford outlines plans for line extensions and tweaks based on customer feedback to enhance device capabilities. The company is set to explore additional applications for the technology in procedures beyond the upper and lower gastrointestinal areas. He goes on to acknowledge the challenges in the med-tech market, particularly the regulatory process, and commended his team for navigating the complexities. He says he's "very happy with where we are at the moment." Despite the regulatory hurdles, Gulliford expressed satisfaction with the steady growth and progress across all facets of the business. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 13, 2023 02:10 PM Eastern Standard Time

Video

Classiq Announces Quantum Center for Life Sciences in Collaboration with NVIDIA

Classiq Technologies

Quantum software pioneer Classiq today unveiled a new industry initiative, the Quantum Computing for Life Sciences & Healthcare Center, formed in collaboration with NVIDIA and the Tel Aviv Sourasky Medical Center. The initiative will champion the development and implementation of quantum algorithms and applications, targeting their transformative potential on life sciences and healthcare. Quantum computing, with the potential to process multifaceted data at unparalleled speeds, may play a pivotal role in reinventing domains like drug discovery, molecular analysis and bespoke medical treatment strategies. Beyond these domains, quantum computing may also be leveraged to address the challenges within supply chain and treatment coordination. By optimizing pharmaceutical supply chains, quantum may ensure the timely and efficient delivery of critical medications. For example, by aiding in treatment coordination, it could streamline patient care, ensuring optimized and personalized therapeutic journeys based on individual medical histories and real-time health data. Classiq CEO Nir Minerbi said, “The opportunities for quantum computing and especially the software that drives it are growing very quickly. The new Quantum Computing for Life Sciences & Healthcare Center aspires to bridge the gap between quantum theory and practice with tangible benefits in life sciences, healthcare and beyond.” In collaboration with NVIDIA, Classiq will establish a multifaceted research landscape. Leveraging NVIDIA H100 Tensor Core GPU capabilities, along with the integration between the NVIDIA CUDA Quantum programming platform and Classiq’s software infrastructure, the center is set to offer a robust environment for quantum-centric innovations and training non-quantum experts. “Integrated quantum-classical computing holds great potential for powering breakthroughs in life sciences and healthcare, but many challenges to realizing that potential remain yet to be addressed,” said Tim Costa, Director of High-Performance Computing and Quantum at NVIDIA. “The Classiq Quantum Computing for Life Sciences & Healthcare Center, built on NVIDIA CUDA Quantum, aims to help researchers tackle these challenges and push the boundaries in applying quantum computing to problems in this critical area.” Initiating the center’s collaborative approach is the renowned Tel Aviv Sourasky Medical Center (Ichilov Hospital). Celebrated for its progressive technological adoptions and pioneering AI integrations since 2014, this institution embodies the future-ready ethos of the healthcare sector. Prof. Roni Gamzu of the Tel Aviv Sourasky Medical Center said, “Clinical and operational activities are typically managed at Ichilov Hospital through smart, data-driven computing systems. We are proud of our achievements but at the same time very much aware that currently available tools are not efficient enough to provide solutions to the steadily growing complexity of our systems. For this exact reason, we are delighted to announce the opening of the first quantum computing lab here at Ichilov. Together with Classiq and NVIDIA, we will break the boundaries of data science for the benefit of medicine and patients. I am convinced that this unique initiative will pave the way for a radically novel approach to data management in health organizations to the benefit of our patients and society at large.” With the Quantum Computing for Life Sciences & Healthcare Center, Classiq and its collaborators are poised to tap into quantum capabilities to propel life sciences and healthcare into a future with potential for greater precision, efficiency and innovation. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform (IDE, complier and OS) with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equips customers to take full advantage of the quantum computing revolution. A low-code development environment ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiqâs world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter), or YouTube, or visit www.classiq.io to learn more. Contact Details Rainier Communciations on behalf of Classiq Michelle Allard McMahon/Jenna Beaucage classiqPR@rainierco.com Company Website http://www.classiq.io/

November 13, 2023 09:00 AM Eastern Standard Time

K3 Elevates Commitment to Homeless Veterans' Lives through PATH Partnership

K3 Holdings

K3 Holdings, a prominent privately held real estate investment firm boasting an expansive nationwide portfolio, is commemorating Veterans Day by spotlighting its collaboration with People Assisting The Homeless (PATH). This partnership reflects the company's dedication to transforming challenges into opportunities, particularly addressing the critical issue of homelessness among the veteran community. Through this partnership with PATH, K3 Holdings/Alpine is not only providing shelter but also fostering an environment where veterans can regain their footing and reclaim their independence. As the nation prepares to honor the sacrifices of servicemen and women, K3 Holdings/Alpine is extending profound appreciation to the courageous individuals who have safeguarded the nation. Many veterans reside in properties managed by K3 Holdings/Alpine, enriching the fabric of communities as friends and neighbors. "On this Veterans Day, we are renewing our commitment to stand with our veterans and echoing the sentiment that no hero who defended our freedom should ever be without a home,” stated Nathan Kadisha, Principal of K3 Holdings. “Through our collaboration with PATH, we are not just addressing homelessness, we are building bridges to hope, and a future filled with possibilities. “Veterans residing in K3 Holdings/Alpine-managed properties are not just tenants, they are an integral part of the community fabric,” Nathan Kadisha continued. "As we unite in gratitude for our veterans, let us also unite in action. K3 Holdings/Alpine invites our community to join in support of PATH, ensuring that every veteran, who stood tall for our nation, now stands tall in dignity and security,” stated Michael Kadisha, Principal of K3 Holdings. “Together, we can rewrite the narrative for homeless veterans, providing them with the support they deserve." About K3 Holdings: K3 Holdings is a privately held real estate investment firm committed to transforming communities and improving housing quality and safety. Their extensive investments have led to remarkable enhancements in their property portfolio, reflecting their unwavering commitment to delivering reliable, safe, and comfortable housing options - https://k3holdings.com/. About People Assisting The Homeless (PATH): People Assisting The Homeless (PATH) is a non-profit organization committed to ending homelessness for individuals and families. PATH provides comprehensive services and support, guiding individuals from homelessness to stable housing and brighter futures - https://epath.org/. ### Contact Details Dan Rene +1 202-329-8357 dan@danrene.com

November 10, 2023 04:00 PM Eastern Standard Time

PathAI Announces Research Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions and algorithm deployment expertise with end-to-end central pathology and histology services, today announced it will present research on advances in AI-based approaches through four poster presentations at the American Association for the Study of Liver Diseases Conference on November 10-14 in Boston, Massachusetts. The posters showcase PathAI’s ongoing commitment to cutting-edge research that advances the understanding and treatment of NASH/MASH using AI-powered digital pathology. Machine learning-assisted fibrosis staging in H&E-stained tissue is comparable to staging with Masson’s Trichrome in non-alcoholic steatohepatitis (poster 2070-A) In this research, PathAI demonstrated the utility of its novel, proprietary AI-powered digital pathology product called NASH Explor e TM to detect collagen and fibrosis signals from H&E-stained whole slide images, and enable liver pathologists to accurately stage fibrosis from these H&E images. Furthermore, the co-authors demonstrated that leveraging the AI-derived fibrosis heatmap overlays over H&E whole slide images for fibrosis staging reduced inter-pathologist staging variability relative to staging performed via Masson’s Trichrome. These results motivate further investigation into the potential to reduce the need for Masson’s Trichrome staining in NASH/MASH clinical trial workflows. This work will be presented on Saturday, November 11 from 1:00-2:00 p.m. E.T. AI-based cellular-level characterization of tissue microarchitecture in non-alcoholic steatohepatitis (poster 2006-A) NASH Explore TM is an AI-powered digital pathology tool that enables automated detection, visualization, and zonated quantification of 14 categories of tissue regions and over 10 cell types, producing a panel of >1000 quantitative Human-Interpretable histologic Features (HIFs) from H&E whole slide images of liver biopsy tissue. In this collaborative research project, the co-authors demonstrate the biological validity of the quantitative histologic features generated by NASH Explore TM. This work will be presented on Saturday, November 11 from 1:00-2:00 p.m. E.T. Artificial intelligence-based measurement of non-alcoholic steatohepatitis (AIM-NASH) improves individual pathologists accuracy and decreases inter-pathologist variability in NASH assessment (poster 2010-A) In this study, Artificial Intelligence-based Measurement of Non-Alcoholic Steatohepatitis (AIM-NASH) algorithm was evaluated for accuracy alone and for use as an assistive tool to pathologists in assessment of liver biopsies in a NASH clinical trial population. This research demonstrates that AIM-NASH may help to standardize histologic scoring for NASH by increasing accuracy for lobular inflammation and ballooning, the features most difficult to score in clinical trial populations. Use of AI-assist AIM-NASH also increased agreement between pathologists for all features. This work will be presented on Saturday, November 11 from 8:00-9:00 a.m. E.T. Artificial intelligence-based measurement of NASH Histology (AIM-NASH) recapitulates primary results from Phase 3 study of resmetirom for treatment of NASH/MASH (Abstract #48735) AIM-NASH TM is an AI-powered digital pathology tool that accurately and reproducibly performs NASH CRN scoring of steatosis, ballooning, lobular inflammation, and fibrosis from whole slide images of H&E- and Masson’s Trichrome-stained liver biopsy tissue. In this collaborative research project, the co-authors demonstrate that all primary histologic endpoints that were met by the central pathologists in a Phase 3 study of resmetirom for treatment of NASH/MASH were also met with statistical significance by AIM-NASH, with clear detection of a dose-response. This adds to the existing body of evidence suggesting that AIM-NASH TM detects true drug effect, while also offering highly repeatable and reproducible histologic scoring. This work will be presented on Monday, November 13 from 1:00-2:00 p.m. E.T. Please visit the PathAI booth, D3100, to learn more and meet the team. About PathAI PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications. PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 10, 2023 10:00 AM Eastern Standard Time